Alexander V. Kabanov, Ph.D., Dr.Sci.
Director, Center for Nanotechnology in Drug Delivery
Mescal Swain Ferguson Distinguished Professor, Center for Nanotechnology in Drug Delivery
Adjunct Professor, UNC Department of Biomedical Engineering
125 Mason Farm Road, Marsico Hall, CB# 7362, Chapel Hill, NC, 27599-7362
Alexander “Sasha” Kabanov, Ph.D., Dr.Sci., is the Mescal S. Ferguson Distinguished Professor and director of the Center for Nanotechnology in Drug Delivery at the UNC Eshelman School of Pharmacy and co-director of the Carolina Institute for Nanomedicine at the University of North Carolina at Chapel Hill. Kabanov graduated from M. V. Lomonosov Moscow State University (MSU) in 1984, where he also received Ph.D. in 1987 and D.Sc. in 1990. He started scientific career in Soviet Union and continued it in United States first, in the University of Nebraska Medical Center, Omaha, Nebraska (1994-2012) where he founded the first academic nanomedicine center in the United States (2004-), and then in the University of North Carolina at Chapel Hill (2012-).
Kabanov has conducted pioneering research in the nanomedicine field including the use of polymeric micelles, DNA/polycation complexes, block ionomer complexes, nanogels, nanoparticle-macrophage carriers and exosomes for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system. He co-invented the first polymeric micelle drug to enter clinical trials to treat cancer and has been instrumental in establishment of polymeric micelles as nanotechnology used in clinically approved and marketed products. Kabanov holds 34 United States patents and over 50 foreign patents. He co-founded several companies focusing on therapies of cancers and diseases of the central nervous system.
Kabanov has published more than 300 scientific papers and his work has been cited over 29,000 times (Hirsch index 91 as of January 2018). He was named the Thomson Reuters 2014 Highly Cited Researcher in pharmacology and toxicology and 2016 Clarivate Analytics Russian Highly Cited Researcher in Life Sciences. His cumulative research support in academia as principal investigator has been more than $54 million. His inventions have attracted over $60 million in private, foundation, and company-sponsored R&D funding in industry. He has founded in 2003 the first nanomedicine symposium series in the United States, NanoDDS (held annually since then), organized the annual industry-academia Carolina Nanoformulation Workshop (since 2016). He co-chaired and chaired Gordon Research Conferences “Drug Carriers in Medicine and Biology” (2006) and “Cancer Nanotechnology” (2017).
Kabanov was a founder and director of the NIH Center of Biomedical Research Excellence (CoBRE) “Nebraska Center for Nanomedicine” (2008-2012), and is a Director of NCI’s T32 Carolina Cancer Nanotechnology Training Program. As of January 2018 he has trained 35 graduate students and 30 postdoctoral scientists, of whom 13 have become faculty members. Kabanov is a recipient of a Megagrant from Russian Government (2010-2014) and professor at MSU where he has established a laboratory with the Megagrant support. He is a member of the Science Council of the Ministry of Education and Science of Russian Federation (2015-present), was a chair of the NIH Biomaterials and Biointerfaces Study Section (2006-2008) and has served in a number of other major advisory roles for sciences in the United States and abroad.
PHCY 512: Pharmaceutics and Drug Delivery Systems
MOPH 862: Advanced Physical Pharmacy
MOPH 864: Advanced Drug Delivery
MOPH 738: Nanomedicine
By appointment only
Honors and Awards
2018: Fellow, Controlled Release Society
2018: Life Sciences Award, Triangle Business Journal
2017: Fellow, National Academy of Inventors (NAI)
2017: George Gamow Award
2016: RUSNANOPRIZE Short List
2015: Dresden Senior Fellow
2013: Member, Academia Europaea (The Academy of Europe)
2010: 2010 Russian MegaGrant
1995: NSF CAREER Award
1988: Lenin Komsomol Prize
Highly Cited Researcher: Thompson Reuters/Clarivate Analytics – Pharmacology & Toxicology (2014, 2018), Life Sciences/Russian (2016)
- CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)
- Targeted Magneto-Mechanic Nanotherapeutics for Cancer
- PEGylated Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
- Targeted Core Shell Nanogels for Triple Negative Breast Cancer